ImClone Systems Inc (formerly IMCL)

[p3analyze]

12-week response rate was not a standard endpoint used in oncology - therefore how predictive it will be of PFS and OS will be unknown.

Having said that, the added toxicity of triple may have shortened the treatment duration - and thus lower the chance for success in the future.

This is a medical affairs trial - so may not be respresentative of those in clinical development - which has trial program that essentially mimic the EPIC, the Crystal etc. Third-line rr seem to be rather comparable between the two drugs.

But the short-term threat is alleviated